1-5 of 5
David Mendelson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors

Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shailaja Uttamsingh, Rainer K. Brachmann, David C. Smith
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (24): 7490–7497.
https://doi.org/10.1158/1078-0432.CCR-17-2157
Published: 14 December 2017
View article titled, A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Open the PDF for A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

Jimmy J. Hwang, John Kuruvilla, David Mendelson, Michael J. Pishvaian, J.F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, John L. Marshall
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (15): 4038–4045.
https://doi.org/10.1158/1078-0432.CCR-10-0822
Published: 28 July 2010
View article titled, Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma
Open the PDF for Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma in another window
Includes: Supplementary data
Journal Articles

A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies

D. Ross Camidge, Roy S. Herbst, Michael S. Gordon, S. Gail Eckhardt, Razelle Kurzrock, Blythe Durbin, Josephine Ing, Tanyifor M. Tohnya, Jason Sager, Avi Ashkenazi, Gordon Bray, David Mendelson
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (4): 1256–1263.
https://doi.org/10.1158/1078-0432.CCR-09-1267
Published: 15 February 2010
View article titled, A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
Open the PDF for A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies in another window
Journal Articles

Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors

William P. Tew, Michael Gordon, John Murren, Jakob Dupont, Sandra Pezzulli, Carol Aghajanian, Paul Sabbatini, David Mendelson, Lawrence Schwartz, Scott Gettinger, Amanda Psyrri, Jesse M. Cedarbaum, David R. Spriggs
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (1): 358–366.
https://doi.org/10.1158/1078-0432.CCR-09-2103
Published: 04 January 2010
View article titled, Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors
Open the PDF for Phase 1 Study of Aflibercept Administered Subcutaneously to Patients with Advanced Solid Tumors in another window
Journal Articles

Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer

Roy S. Herbst, Angela M. Davies, Ronald B. Natale, Thao P. Dang, Joan H. Schiller, Linda L. Garland, Vincent A. Miller, David Mendelson, Annick D. Van den Abbeele, Yulia Melenevsky, Daniel J. de Vries, David A. Eberhard, Benjamin Lyons, Stuart G. Lutzker, Bruce E. Johnson
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (20): 6175–6181.
https://doi.org/10.1158/1078-0432.CCR-07-0460
Published: 18 October 2007
View article titled, Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer
Open the PDF for Efficacy and Safety of Single-Agent Pertuzumab, a Human Epidermal Receptor Dimerization Inhibitor, in Patients with Non–Small Cell Lung Cancer in another window